![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgoC8sahLO_s9zIz-k0R3nUwzPu1ORT3_0zGMmQN24iFzU13-3qZGMIDRg4my_7rTROeSwqYhOUkvqIrfjFKKjPL0torcjSZFA_0taEVBLZc0Jonm6FQd3k3UyQy41hpjElfIpn/s400/fda_black_box_warning.gif)
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgnPVYAjVvOZZS_Auh0Yo_NHkuMwvAX-AEo_RHA_ivfUcBYpgDLG2k0NpxNoynehF8gBCkXQfxB6_kYw0dwYFZglwzJYNZbp-nlAaBu1BDJqzZ3zZ1aJs0Id_eDuV-XX48nsTtG/s320/suicidality.jpg)
Attorneys have asked the U.S. Supreme Court to hear the case of a teen sentenced to 30 years in prison for killing his grandparents when he was 12, arguing that the sentence is cruel. Christopher Pittman used a shotgun to shoot his grandparents Joe and Joy Pittman, and then set fire to their home in 2001. During his trial four years later, Pittman's attorneys unsuccessfully argued the slayings were influenced by the antidepressant Zoloft — a charge the maker of the drug vigorously denied.
Zoloft is the most widely prescribed antidepressant in the United States, with 32.7 million prescriptions written in 2003. In 2004, the Food and Drug Administration ordered Zoloft and other antidepressants to carry "black box" warnings — the government's strongest warning short of a ban — about an increased risk of suicidal behavior in children.
The U.S. Food and Drug Administration (FDA) required the makers of all antidepressant medications to update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment (generally the first one to two months).
Historical Information on Antidepressant Use in Children, Adolescents, and Adults is available here. Sure begs a lot of questions concerning how this information, long in the public domain, is not more widely known, covered, and sounded from the rooftops every.single.time there's another adolescent mass murderer and the underlying psycho-pharmacology of the perpetrating adolescent is known?
0 comments:
Post a Comment